HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preclinical toxicology of platinum analogues in dogs.

Abstract
A toxicology study of cis-diamminedichloroplatinum (II) (CDDP), aqua(1,1-bis-(aminomethyl)cyclohexane)sulfatoplatinum(II) (TNO-6), diammine(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA), cis-dichloro-trans-dihydroxo-cis-bis(isopropylamine)platinum-(IV) (CHIP) and ethylenediaminemalonatoplatinum(II) (JM-40) was carried out in dogs. The main purpose of the study was to compare the results with those obtained earlier in mice and rats and with the toxicology data in humans. Each platinum compound was tested in three dogs. Each dog received three intravenous bolus injections at intervals of 3 weeks. The compounds were administered in dosages of 1.2, 1.0, 12, 10 (or 6) and 10 mg/kg, respectively. Toxic death occurred for two dogs (both on day 54) from haematotoxicity (10 mg/kg CHIP) and renal toxicity (TNO-6), respectively. Serum urea nitrogen and creatinine concentrations were variable after TNO-6 and remained within normal values after treatment with the other compounds. Severe proteinuria was observed in all three dogs treated with TNO-6. Values returned to normal within 16 days. JM-40 did not cause significant proteinuria. CDDP, CBDCA and CHIP caused short-lasting and slight proteinuria. CHIP caused a severe reduction in the number of leukocytes and platelets, while the other drugs caused acceptable reductions. Except after the high dose CHIP regimen, haematotoxicity was of a transient nature. Vomiting in order of severity occurred after TNO-6, CHIP, CDDP and JM-40, while CBDCA did not cause any vomiting. The dogs were sacrificed 6 weeks after the last drug dose. Organs were fixed for histopathology to complete and support clinical-toxicological parameters. On the basis of the results from the single-dose study in dogs and those obtained earlier in mice and rats it can be concluded that the gain from the use of the dog as a prognosticator for organ toxicity in man was disappointing and limited to the prediction of vomiting.
AuthorsP Lelieveld, W J van der Vijgh, D van Velzen
JournalEuropean journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 23 Issue 8 Pg. 1147-54 (Aug 1987) ISSN: 0277-5379 [Print] England
PMID3308482 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Organoplatinum Compounds
  • ethylenediamine platinum(II) malonate
  • iproplatin
  • Urea
  • Creatinine
  • Carboplatin
  • spiroplatin
  • Cisplatin
Topics
  • Animals
  • Body Weight (drug effects)
  • Carboplatin
  • Cisplatin (toxicity)
  • Creatinine (blood)
  • Dogs
  • Dose-Response Relationship, Drug
  • Kidney Diseases (chemically induced)
  • Leukocyte Count (drug effects)
  • Male
  • Organoplatinum Compounds (toxicity)
  • Platelet Count (drug effects)
  • Proteinuria (chemically induced)
  • Urea (blood)
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: